Condition: Urothelial Carcinoma · Sponsor: Merck Sharp & Dohme LLC
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045) | Orange, California, United States | Recruiting |
| University of California San Francisco ( Site 1044) | San Francisco, California, United States | Recruiting |
| Anschutz Cancer Pavilion ( Site 1017) | Aurora, Colorado, United States | Completed |
| University of Chicago Medical Center ( Site 1037) | Chicago, Illinois, United States | Recruiting |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 1011) | Indianapolis, Indiana, United States | Recruiting |
| Siteman Cancer Center ( Site 1038) | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 1031) | New York, New York, United States | Recruiting |
| Cleveland Clinic-Taussig Cancer Center ( Site 1036) | Cleveland, Ohio, United States | Recruiting |
| UPMC Hillman Cancer Center ( Site 1014) | Pittsburgh, Pennsylvania, United States | Recruiting |
| Huntsman Cancer Institute ( Site 1041) | Salt Lake City, Utah, United States | Recruiting |
| Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952) | Brisbane, Queensland, Australia | Completed |
| Princess Margaret Cancer Centre ( Site 1106) | Toronto, Ontario, Canada | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05562830